[The Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma(2018)].

Although addition of novel monoclonal antibodies, targeted therapies, and immune therapies have remarkably improved both response and long-term survival of malignant lymphoma, hematopoietic stem cell transplantation (HSCT) remains an important therapeutic option for lymphomas. In order to improve the understanding of the roles of hematopoietic stem cell transplantation for malignant lymphoma and further standardize the clinical application, the Chinese experts from the Hematology Oncology Committee of China Anti-Cancer Association, the Leukemia & Lymphoma Group of the Society of Hematology at Chinese Medical Association and the Chinese Union of Lymphoma Research of the Chinese Society of Clinical Oncology, have analyzed the related research data and developed the Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma(2018). In this consensus, we have systematically expounded on the indication, type of transplant, mobilization and collection of hematopoietic stem cells, conditioning regimen, pre-or post transplant therapies and follow-up of HSCT for malignant lymphoma, in order to provide reference for clinicians.